Suven Life Sciences Ltd

- For FY19-20, all CAPEX and Rising Pharma investments will be funded through internal accruals. - If needed, loans may be taken specifically for assets related to CAPEX. - There is no explicit mention of new equity fundraising. - Finance cost is currently negligible and expected to grow only marginally (10%-15% growth in business). - The company is comfortable with its cash position for future R&D spends, relying mainly on internal accruals. - No concerns expressed regarding additional funding needs even if innovative molecule SUVN-502 does not succeed. In summary, the company plans to fund its CAPEX and business expansions primarily through internal accruals with potential limited debt for asset acquisitions, with no indicated plans for new equity fundraising.

- CAPEX guidance for FY20 is around Rs. 200 crore, primarily for new projects including the formulation development center and a new block in Vizag. - Maintenance CAPEX is estimated at Rs. 30-40 crore based on requirements. - The company is constructing a new formulation manufacturing facility expected to add substantial revenue 3-4 years from now. - Rs. 35 million USD investment made upfront (day #1) for a 25% minority stake in Rising Pharma (Suven Shore), a virtual pharma company with about $200 million sales currently. - This strategic investment aims to leverage ANDA development, manufacturing, and supply for future business growth. - The investment is expected to create value over 5 years, with a potential 4x increase in valuation. - Funding requirements including CAPEX and Rising Pharma investments are expected to be met through internal accruals, with minimal financing needs.

- Core CRAMS business expected to grow 10%-15% (Venkat Jasti, Page 14). - Commercial CRAMS to increase from Rs. 80 crore to around Rs. 130 crore (Page 9). - Specialty Chemicals expected to remain stable at Rs. 200-215 crore without significant growth (Page 4). - Rising Pharma virtual company’s sales expected to start at $200 million and ramp up to $340-$360 million in 2-3 years (Page 6). - New formulation manufacturing facility under construction, expected to add substantial revenue in 3-4 years (Page 11). - For FY20, one or two commercial operations targeted in the formulation division (Page 16). - CRAMS overall expected growth of 15%-20% (Page 9). - Bottom-line guidance of 20% growth for FY20 standalone (Page 14,16).

- Guidance is for **20% growth in bottom-line (PAT)** for FY20 on a standalone basis (Page 16). - Core CRAMS business is expected to grow by **10%-15%** with commercial orders increasing (Page 16). - Specialty Chemicals sales expected to remain stable around Rs. 200-215 crore (Page 15). - Formulation division capacity and commercial operations to start contributing from next year onward, with 1-2 commercial operations expected in FY20 mostly in the second half (Page 16). - EBITDA margin for Suven Pharma in FY19 was 36% post R&D, with overall PAT guided to grow 20% for FY20 (Page 15). - No near-term revenue expected from minority investments (e.g., Rising Pharma); value expected through indirect benefits and strategic growth over 3-5 years (Pages 3 and 6). - Finance cost remains negligible; CAPEX primarily internally funded (Page 11).

- Core CRAMS orderbook for Q4 FY19 is about Rs. 113.8 crore. - Commercial CRAMS orders stand at Rs. 42 crore within the core CRAMS. - Specialty chemicals sales for the full year are around Rs. 210-215 crore, expected to remain stable next year. - Expected 10%-15% growth on core CRAMS business in FY20. - Commercial CRAMS expected to increase from Rs. 80 crore to Rs. 130 crore in FY20. - Specialty chemicals to maintain current levels based on customer indications. - Formulation division capacity and commercial operations are expected to start next year with 1-2 commercial operations targeted in FY20. - CRAMS business works on campaign basis with 60-70 products annually; reactors are fully occupied but capacity utilization calculation is complex due to different product needs.